Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.
about
Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.Current status and future prospects for biologic treatments of psoriasis.Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.Treating moderate to severe psoriasis - best use of biologics.Systemic therapies for psoriasis: an evidence-based update.Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris.CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.Secukinumab (AIN457) for the treatment of psoriasis.Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC.Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials.Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis.Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection.
P2860
Q35658540-DF1A7171-8DDC-4FF9-85F3-A5F7CFDB0952Q35860158-3A923625-C0B2-4082-8AC5-9CF75C73F573Q36057909-E82B2421-D5F4-468E-9D06-92A82836352BQ36628064-A41CB482-1D07-4D70-93BB-CAFAAB656F61Q37295966-59E99E1E-6677-4982-A347-E7CB2BEB85D5Q38153077-B88BCB3A-BF80-4DDF-B4FD-974C9AAB1697Q38174153-B5042E28-4C7F-440B-A78B-4433BA4A8BB2Q38185297-1F1E4D0E-D4DA-4E02-A734-1790FD5598DDQ38196879-A26EFE38-229F-4A21-AAAD-402893C24B23Q38411982-7ACF1647-7F26-44AD-82DF-F03BAD59A818Q38597111-0D8DF0C7-F6BA-419B-BD1D-8369228B4EA2Q38608215-9476472A-3390-4D1A-97C6-BDD22D64DADDQ38644270-C83DC082-CB98-4CAF-A5DD-A04EAA42202EQ38727735-1BE9B5F7-A9B8-4B16-9D10-461CFAD0C0A8Q38764424-05E8A316-0ADA-4E79-9C67-90F872F50384Q39601823-93A0C655-D860-4BD2-B9D5-9203C62D83C3Q44477550-F0BEE46B-A658-4406-AB4B-299043E94D10Q47595988-745F6181-4B3F-4286-9154-B51ECAFB132AQ47671991-2A0EE444-55E7-4FB6-857D-755456B6B087Q48051795-D2A0D0E7-D1AF-47A9-BF1D-1D8A47DBF61AQ49860352-C6E4C865-1222-4178-8BA4-EA1B13F560F9Q52672846-2F9A043A-C0CA-45E1-B413-D234C3E45A39
P2860
Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Which antipsoriatic drug has t ...... pidity of the onset of action.
@en
type
label
Which antipsoriatic drug has t ...... pidity of the onset of action.
@en
prefLabel
Which antipsoriatic drug has t ...... pidity of the onset of action.
@en
P2093
P356
P1476
Which antipsoriatic drug has t ...... apidity of the onset of action
@en
P2093
Alexander Nast
Anja Jacobs
Birte Sporbeck
Delano Pathirana
Jochen Schmitt
Stefanie Rosumeck
P2888
P304
P356
10.1038/JID.2013.78
P407
P577
2013-02-20T00:00:00Z
P5875
P6179
1028358364